DOI: https://doi.org/10.22141/2224-0586.16.4.2020.207928

Nitrates in clinical practice

V.V. Nikonov, Ye.I. Kinoshenko, S.V. Kursov

Abstract


In recent years, the field of application of nitrates in cardiology has undergone certain changes. The widespread use of thrombolytic drugs in acute myocardial infarction has led to a decrease in the frequency of using intravenous nitrates in this pathology, and the widespread use of angiotensin-converting enzyme inhibitors and the expansion of the indications for the administration of angiotensin II receptor antagonists (sartans) for heart failure have helped to limit the use of nitrates in the treatment of such patients. But despite new developments and approaches to the therapy of coronary heart disease, nitrates are one of the important groups of drugs. With stable angina pectoris, nitrates relieve ischemic pain, prevent the development of anginal syndrome and increase patients’ exercise tolerance. In acute coronary syndrome, nitrates stop a pain attack, prevent left ventricular remodeling after myocardial infarction, improve the state of intracardiac and systemic hemodynamics, reduce the size of the zone of myocardial infarction and decrease the incidence of hospital-acquired cardiovascular complications. Intravenous and oral administration of nitrates during and after thrombolytic therapy in patients with ST-segment elevation acute myocardial infarction shows a tendency to decrease their mortality. At the same time, the use of nitrates in patients at risk (women and elderly patients) or their combined use with angiotensin-converting enzyme inhibitors, as shown by the ISIS-4 and GISSI-3 trials, significantly reduces the mortality of patients with ST-segment ele­vation acute myocardial infarction. In patients with heart failure, nitrates significantly improve the clinical symptoms and the state of systemic hemodynamics, and when used together with hydralazine, as shown by the VHeFT-l study, they reduce their mortality. Moreover, the scope of nitrate use in modern medical practice is not limi­ted only to patients with coronary heart disease and heart failure. Nitrates are widely used in the treatment of hypertensive crises and pulmonary edema. Nitrates are often prescribed for patients with portal hypertension and pulmonary hypertension (to reduce pressure in the corresponding vascular systems). As antispasmodics, nitrates can be used to stop colic in patients with gallstone disease and urolithiasis. There are reports on the effective use of nitrates in obstetric practice (with threatened miscarriage and fetal distress), as well as in ophthalmology (with retinal thrombosis). The data presented indicate that nitrates, as before, deserve close attention and wider use in clinical practice.


Keywords


nitrates; coronary heart disease; myocardial infarction; portal hypertension

References


Ольбинская Л.И., Морозова Т.Е. Современные аспекты фармакотерапии ишемической болезни сердца. Лечащий врач. 2003. № 6.

Рекомендации по лечению стабильной ишемической болезни сердца. ESC 2013. Российский кардиологический журнал. 2014. № 7 (111).

World Health Organization. Preventing chronic diseases a vital investment. Overview. WHO 2005. http://www.who.int/chp/chronic_disease_report

Роуз Дж., Блекберн Г., Гиллум Р.Ф., Принеас Р. Дж. Эпидемиологические методы изучения сердечно-сосудистых заболеваний. 2-е изд. Женева: ВОЗ, 1984. 224 с.

Anderson J.L., Adams C.D., Antman E.M. et al. Recommendations of the American College of Cardiolodgy. American Association on Management of Patients With Unstable Angina. Miocardial Infarction without ST Segment Elevation. J. Am. Coll. Cardiol. 2007. 50. 1-157.

Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007. 28. 2375-2414.

Brorsson B., Bernstein S.J., Brook R.H., Werkö L.; for the SECOR/SBU Project Group. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002 February. 87 (2). 140-145.

Бобрышев К.А. Органические нитраты как интегральная часть оптимальной консервативной терапии стабильной ишемической болезни сердца. Серцева недостатність та коморбідні стани. 2017. № 3.

Осадчий А.И. Ишемическая болезнь сердца. Рекомендации по реваскуляризации 2018 г. Укр. мед. часопис. 2018.

Лутай М.И., Лысенко А.Ф., Слободской В.А., Ткаченко Л.М. Применение органических нитратов в современной терапии при стабильной ишемической болезни сердца. Укр. мед. часопис. 2014. № 4 (102). VII/VIII.

Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых средств. 2-е изд. М.: БИНОМ; СПб.: Невский Диалект, 2002.

Thadani U., Lipicky R.J. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc. Drugs Ther. 1994. 8 (4). 611-623.

Abrams J. How to use nitrates. Cardiovasc. Drugs Ther. 2002. 16 (6). 511-514.

Аронов Д.М., Лупанов В.П. Дифференцированное применение нитратов при ишемической болезни сердца в зависимости от формы и тяжести заболевания. Кардиология. 2006. 1. 74-82.

Murrell W. Nitro-glycerine as a remedy for angina pectoris. Lancet. 1879. 1. 80-81.

Марцевич С.Ю. Роль нитратов в лечении ишемической болезни сердца на современном этапе. Кардиология. 2009. 6. 12-16.

Лупанов В.П. Применение нитратов у больных хронической ишемической болезнью сердца. Трудный пациент. Июль 2011. 5. 23-25

Лупанов В.П. Нитраты в лечении больных ишемической болезнью сердца: фокус на изосорбида динитрат. Медицинский совет. 2015. № 6. 35-37.

Инструкция по применению препарата Изокет спрей.

Münzel Т. Neue Erkenntnisse bei der Nitratwirkung, Nitratbioaktivierung und Toleranzentwicklung Recent studies on nitrates: their action, bioactivation and development of tolerance. Dtsch. Med. Wochenschr. 2008. 133. 2277-2282.

Евдокимова А.Г., Евдокимов В.В., Кожина Н.А. Применение нитратов в лечении больных ишемической болезнью сердца. Место аэрозольных форм. КиберЛенинка: https://cyberleninka.ru/article/n/primenenie-nitratov-v-lechenii-bolnyh-ishemicheskoy-boleznyu-serdtsa-mesto-aerozolnyh-form

Marmor A. Comparative evaluation of new formulation of isosorbide dinitrate oral spray and sublingual nitroglycerin tablets. Am. J. Cardiol. 1990. 65. 43-45.

Кириченко А.А. Эффективность ингаляционной формы Изокета у больных стенокардией. Медицинский совет. 2015. № 4. 56-58.

ACC/AHA/ACP-ACIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Amer. Coll. Cardiol. 1999. 33. 2092-2198.

Егоров В.А., Семенова Ю.Э. Роль нитратов в современной терапии ишемической болезни сердца. Лечащий врач. 2005. № 4. 56-59.

Карпов Ю.А. Хроническая ишемическая болезнь сердца: новости лечения. Consilium Medicum. 2016. № 1. Т. 18.

Лупанов В.П. Нитраты при ишемической болезни сердца в зависимости от клинической формы и тяжести заболевания. Consilium Medicum. 2006. 5. 91-99.

Беленков Ю.Н., Чазова И.Е., Ратова Л.Т. и др. Результаты международного исследования качества жизни пациентов со стабильной стенокардией на фоне терапии нитратами (IQOLAN). Кардиология. 2003. 9. 4-7.




Copyright (c) 2020 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта